Literature DB >> 18434754

Expression of TLR4 and TLR9 mRNA in Lewis rats with experimental allergic neuritis.

Yong-Ning Deng1, Wen-Bin Zhou.   

Abstract

OBJECTIVE: Experimental autoimmune neuritis (EAN) is a T cell-mediated animal model of the Guillain-Barré syndrome characterized by inflammation and demyelination of the peripheral nervous system (PNS). The key pathogenesis of EAN is the imbalance between Th1- and Th2-type immune response. Toll-like receptor (TLR) is a receptor of the innate immune system. It can recognize the antigen by pathogen-associated molecular patterns, and activate the antigen-presenting cells, producing costimulating molecules to activate T cells. In this study, we observed the expression of mRNA of TLR4 and TLR9 in EAN rats.
METHODS: Male Lewis rats were immunized with the component of PNS myelin sheath protein P0 180-199 (100 microg) and Freund's complete adjuvant (CFA). The clinical signs of rats and the pathological changes in the sciatic nerves were observed. The rats in the immunized group and the control group were sacrificed on day 7, 16, 24 and 33 after immunization. To observe the histopathological changes, sciatic nerve was embedded in paraffin, sectioned and stained with HE and Weil's stain. The mRNA expression of TLR4 and TLR9 in spleen, sciatic nerve, peripheral blood monocytes and lymph nodes was detected by reverse transcriptase PCR dynamically.
RESULTS: The EAN group reached the peak of the clinical score at day 16 after the immunization, and the clinical manifestation obviously improved at day 33 after the immunization. The mRNA expression of TLR4 peaked at day 16, then decreased gradually, but at day 33, it was still higher than that of the CFA control group (p < 0.05); there were significant differences among the four time points (p < 0.05). The mRNA expression of TLR9 was upregulated during the entire course of EAN compared to the CFA and the control group (p < 0.05).
CONCLUSIONS: TLR4 and TLR9 may play a role in the pathogenesis of EAN by taking part in the activation phage and effector phage. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434754     DOI: 10.1159/000127433

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  10 in total

1.  Outcomes of toll-like receptors' antagonism in steroid-resistant optic neuritis; a pilot study.

Authors:  Aditya Sudhalkar; Mayuri Khamar; Bakulesh Khamar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-15       Impact factor: 3.117

2.  Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis.

Authors:  Yu-Zhong Wang; Mei Yan; Fa-Fa Tian; Jun-Mei Zhang; Qun Liu; Huan Yang; Wen-Bin Zhou; Jing Li
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

Review 3.  Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome.

Authors:  Kishan Kumar Nyati; Kashi Nath Prasad
Journal:  Mediators Inflamm       Date:  2014-09-22       Impact factor: 4.711

Review 4.  Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions.

Authors:  Robert Root-Bernstein
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

5.  Toll-like receptor-4 299Gly allele is associated with Guillain-Barré syndrome in Bangladesh.

Authors:  Israt Jahan; Rijwan U Ahammad; Mir M Khalid; Mohammad I Rahman; Shoma Hayat; Badrul Islam; Quazi D Mohammad; Zhahirul Islam
Journal:  Ann Clin Transl Neurol       Date:  2019-03-03       Impact factor: 4.511

6.  Inhibition of TLR4 signaling protects mice from sensory and motor dysfunction in an animal model of autoimmune peripheral neuropathy.

Authors:  Oladayo Oladiran; Xiang Qun Shi; Mu Yang; Sylvie Fournier; Ji Zhang
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

Review 7.  Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems.

Authors:  Haixia Li; Shan Liu; Jinming Han; Shengxian Li; Xiaoyan Gao; Meng Wang; Jie Zhu; Tao Jin
Journal:  Front Immunol       Date:  2021-11-01       Impact factor: 7.561

8.  TAK-242 ameliorates epileptic symptoms in mice by inhibiting the TLR4/NF-κB signaling pathway.

Authors:  Jibo Dong; Yong Liao; Bihua Wu
Journal:  Ann Transl Med       Date:  2022-07

9.  Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells.

Authors:  Thomas Grüter; Alina Blusch; Jeremias Motte; Melissa Sgodzai; Hussein Bachir; Rafael Klimas; Björn Ambrosius; Ralf Gold; Gisa Ellrichmann; Kalliopi Pitarokoili
Journal:  J Neuroinflammation       Date:  2020-05-06       Impact factor: 8.322

10.  DHA modulates MANF and TREM2 abundance, enhances neurogenesis, reduces infarct size, and improves neurological function after experimental ischemic stroke.

Authors:  Ludmila Belayev; Sung-Ha Hong; Raul S Freitas; Hemant Menghani; Shawn J Marcell; Larissa Khoutorova; Pranab K Mukherjee; Madigan M Reid; Reinaldo B Oria; Nicolas G Bazan
Journal:  CNS Neurosci Ther       Date:  2020-08-05       Impact factor: 5.243

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.